Search
Menu
Home
HTB
2019
October
HTB
October 2019
Contents
Editorial
HTB 18 October 2019 online
Conference reports
IDWeek (2019), 2–6 October 2019, Washington DC
HIV suppression and safety with ibalizumab at 48 weeks in expanded access
Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study
Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available
Switching from TDF to TAF linked to higher BMI and cardio risk
Possible higher diabetes risk with raltegravir or PIs than NNRTIs
Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives
Over half of mostly black US HIV group has NAFLD – and many have NASH
People taking more medications and women have higher fall risk in older HIV group
No link between raltegravir and adverse birth outcomes in analysis in 2550 women
PrEP linked to lower HIV incidence in US, independent of TasP
Antiretrovirals
Dual dolutegravir/lamivudine submitted to US FDA as switch option
Treatment access
UK contributes £1.4 billion towards Global Fund for 2020 to 2022
Global Fund raises US$14 billion for 2020 to 2022
Guidelines
NHS England best practice in HIV prescribing and multidisciplinary teams
HIV prevention and transmission
US approves F/TAF for PrEP (Descovy): indication excludes risk from receptive vaginal sex
Basic science and immunology
Science journal retracts article linking CCR5 deletion to reduced life expectancy
PDFs
18 October 2019 vol 20 no 12
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
HIV diagnoses in England jump by 51% in 2023: missing targets and highlighting disparities in access to care
6 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage